-
Idecabtagene vicleucel, sold
under the
brand name
Abecma, is a cell-based gene
therapy to
treat multiple myeloma. The most
common side
effects include...
- (INN)
abatacept (USAN)
Abasol Abbokinase abciximab (INN)
abecarnil (INN)
Abecma abediterol (INN)
Abegrin Abelcet Abenol Abevmy abexinostat (USAN, INN) Abilify...
-
Archived from the
original on 8
December 2023.
Retrieved 8
December 2023. "
Abecma (idecabtagene vicleucel)". U.S. Food and Drug
Administration (FDA). 21 April...
-
Evaluation and
Research (2021-03-27). "
ABECMA (idecabtagene vicleucel)". FDA.
European Medicines Agency (2023-07-27). "
Abecma". EMA.
Center for
Biologics Evaluation...
-
medical use in the
United States in
September 2023.
Idecabtagene vicleucel (
Abecma) –
first cell-based gene
therapy was
approved by FDA in 2021 for the treatment...
- (triamcinolone acetonide) Kenalog-40 (triamcinolone acetonide)
Oncology Abecma (idecabtagene vicleucel)
BiCNU (carmustine)
Breyanzi (lisocabtagene maraleucel)...
-
treatment for head and neck
squamous cell
carcinoma Idecabtagene vicleucel (
Abecma):
treatment for
multiple myeloma Lovotibeglogene autotemcel (Lyfgenia):...
- The U.S. Food and Drug
Administration (FDA)
approves Abecma to
treat multiple myeloma.
Abecma is the
first cell-based gene
therapy approved by the FDA...
-
Breyanzi (lisocabtagene maraleucel),
Carvykti (ciltacabtagene autoleucel),
Abecma (idecabtagene vicleucel), and
Kymriah (tisagenlecleucel). "Hackensack Meridian...
- Clevecord, and Omisirge); CART
products (Kymriah, Yescarta, Tecartus, Breyanzi,
Abecma, and Carvykti); gene
therapies Zynteglo, Casgevy, Skysona, and Lyfgenia;...
